文献速递生殖医学

对监管未来生殖技术临床实施存在广泛支持

Broad support for regulating the clinical implementation of future reproductive techniques.
PubMed 文献 · Hum Reprod · 2018-01-01

该横断面调查在荷兰冬季2015-2016年开展,纳入179名生殖门诊妇科医生、348名严重不孕患者和1250名公众代表。958人完成问卷(应答率54%),各群体中超过85%的人希望至少对一种干细胞生育治疗临床实施的潜在负面后果进行监管。各群体多数倾向于由国家生物伦理委员会作为监管机构。

要点

  • 各参与者群体中超过85%的人希望至少对一种干细胞生育治疗临床实施的潜在负面后果进行监管。
  • 各群体多数希望监管预期父母严重健康风险、子代严重健康风险和人类胚胎处置。
  • 各群体多数倾向于由国家生物伦理委员会作为监管机构并咨询不同背景顾问。

核心结论

  • 妇科医生、患者和公众广泛支持对未来干细胞生育治疗的临床实施进行监管。
  • 多数参与者倾向于由国家生物伦理委员会作为监管机构,并咨询不同背景的顾问。

研究设计与样本

  • 横断面调查,纳入在生殖门诊工作的妇科医生(n=179)、严重不孕患者(n=348)和公众代表样本(n=1250)。
  • 问卷于2015-2016年冬季在荷兰发放,共958人完成问卷,应答率54%。

主要发现

  • 各参与者群体中超过85%的人希望至少对一种干细胞生育治疗临床实施的潜在负面后果进行监管。
  • 各群体多数希望监管预期父母严重健康风险、子代严重健康风险和人类胚胎处置。
  • 对自付费用和治疗负担的监管支持度较低。
  • 多数妇科医生和公众但非患者要求监管轻微先天异常风险、成功率和治疗自然性,而多数患者认为前两项潜在负面后果重要。
  • 各群体多数倾向于由国家生物伦理委员会作为监管机构,该委员会应咨询不同背景顾问并考虑更广泛的潜在后果背景。

临床怎么用

  • 作者认为,国家生物伦理委员会应咨询不同背景顾问,以监管未来干细胞生育治疗的临床实施。
  • 作者认为,这种对监管的广泛支持是否适用于其他医学领域的新技术应予以检验。

局限性

  • 本实证研究仅关注三个利益相关群体。
  • 本研究报告的是多数人的观点,而这并非必然是道德上正确的观点。
  • 研究结果对其他文化和其它技术的可迁移性仍不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do gynaecologists, infertile patients and the general public, consider that regulation of the clinical implementation of stem cell-based fertility treatments is required? SUMMARY ANSWER: There is broad support from gynaecologists, patients and the general public for regulating the clinical implementation of future stem cell-based fertility treatments. WHAT IS KNOWN ALREADY: There is debate on the need to regulate the clinical implementation of novel techniques. Regulation may hinder their swift adoption and delay benefits for patients, but may prevent the implementation of ineffective or harmful techniques. Stem cell-based fertility treatments, which involve creating oocytes or spermatozoa by manipulating stem cells, are likely to be implemented in clinical practice in the near future and will probably impact future generations as well as the current one. STUDY DESIGN, SIZE, DURATION: A cross-sectional survey was conducted among gynaecologists working in fertility clinics (n = 179), patients with severe infertility (n = 348) and a representative sample of the general public (n = 1250). The questionnaire was disseminated in the Netherlands in the winter of 2015-2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: The newly developed questionnaire was reviewed by experts and tested among the general public. The questionnaire assessed whether participants wanted each of nine potential negative consequences of the clinical implementation of stem cell-based fertility treatments to be regulated. In addition, the importance of all negative and positive potential consequences, the appropriate regulatory body and its need to consult with advisors from various backgrounds was questioned. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 958 respondents completed the questionnaire (response rate: 54%). A large majority of each participant group (>85%) wanted regulation, for at least one potential negative consequence of the clinical implementation of stem cell-based fertility treatments. The majority of all participant groups wanted regulation for serious health risks for intended parents, serious health risks for children and the disposal of human embryos. Regulation for out-of-pocket costs and the burden of treatment received little support. The majority of gynaecologists and the general public, but not the patients, requested regulation for the risk of minor congenital abnormalities, the success rates and the naturalness of treatments. Nevertheless, the majority of patients did consider the former two potential negative consequences important. The majority of all groups preferred a national bioethics committee as the regulatory body. This committee should consult with advisors from various backgrounds and should consider the broader context of potential consequences of the stem cell-based fertility treatments. LIMITATIONS, REASONS FOR CAUTION: This empirical study focuses on only three stakeholder groups. This study reports on the perspective of the majority and this is not per definition the morally right perspective. The transferability of our findings to other cultures and other techniques remains unclear. WIDER IMPLICATIONS OF THE FINDINGS: A national bioethics committee, consulting with advisors from various backgrounds, should regulate the clinical implementation of future stem cell-based fertility treatments. Whether this broad support for regulation applies to novel techniques from other fields of medicine should be examined. STUDY FUNDING/COMPETING INTEREST(S): The Young Academy of the Royal Netherlands Academy of Arts and Sciences. None of the authors has any conflict of interest to declare. TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Hendriks S, Vliegenthart R, Repping S, et al. Broad support for regulating the clinical implementation of future reproductive techniques. Hum Reprod. 2018. PMID: 29190346. doi:10.1093/humrep/dex355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。